Coronary heart disease prevention: Insights from modelling incremental cost effectiveness

British Medical Journal

Volumn 327, Issue 7426, 2003, Pages 1264-1267

  Marshall, Tom ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b PARTNERS HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; CLOPIDOGREL; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ARTICLE; CALCULATION; CONTROLLED STUDY; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT PLANNING;

EID: 0345172347     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.327.7426.1264     Document Type: Article

References (15)

1. Department of Health. Chapter 2: Preventing coronary heart disease in high risk patients. In: National service framework for coronary heart disease. London: DoH, 2000:1-32.
2. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2002;324:1570-6.
3. National Institute for Clinical Excellence. NICE technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. London: NICE, 2001.
4. Netten A, Curtil L. Unit costs of health and social care 2001. Canterbury: Personal Social Services Research Unit, University of Kent, 2001.
5. British Medical Association, Royal Pharmaceutical Society of Great Britain. British national formulary. London: BMA, RPS, 2002. (No 44.)
6. Prescription Pricing Authority. Drug tariff. London: Stationery Office, 2002.
7. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
8. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2):S1-29.
9. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of coronary events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;136:161-72.
10. Gaspoz J-M, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MGM, et al. Cost-effectiveness of aspirin, clopidogrel, or both for secondary prevention coronary heart disease. N Engl J Med 2002;346:1800-6.
11. Ebrahim S, Davey Smith G, McCabe C, Payne N, Pickin M, Sheldon TA, et al. What role for statins? A review and economic model. Health Technol Assess 1999;3(19):i-iv, 1-91.
12. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-64.
13. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al, for the INDANA Investigators. Effect of antihypertensive drug treatment on coronary outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med 1997;126:761-7.
14. Department of Health. National service framework for coronary heart disease. London: DoH, 2000.
15. Health Survey for England 1998. London: Stationery Office, 2000.